HAS
INO icon

HBW Advisory Services’s Inovio Pharmaceuticals INO Stock Holding History

HBW Advisory Services’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-842
Closed -$94K – 266
2021
Q1 		$94K Buy
+842
New +$111K 0.03% 240

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HBW Advisory Services's INO Position: Q2 2021 in Review

HBW Advisory Services sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 842 shares — an estimated $94K sold.

HBW Advisory Services first reported a position in INO in Q1 2021 and held it in 1 quarter. The position peaked at $94K in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

  • HBW Advisory Services reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HBW Advisory Services sold 842 Inovio Pharmaceuticals shares in Q2 2021, an estimated $94K.
  • HBW Advisory Services first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • HBW Advisory Services's Inovio Pharmaceuticals position peaked at $94K in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on HBW Advisory Services's 13F filing for Q2 2021, filed 15 Jul 2021.